NICE nixes BioMarin's ultra-orphan therapy for lack of long-term data

The U.K.'s NICE did not recommend Brineura cerliponase alfa from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) due to uncertainty around the therapy's long-term efficacy and concerns NHS would be unable to implement the rare disease biotech's proposed

Read the full 354 word article

How to gain access

Continue reading with a
two-week free trial.